药明合联（02268）：蓄势待发，全球领先的XDC CRDMO有望进入商业化收获期

Investment Rating - The report assigns a "Buy" rating to WuXi XDC (02268.HK) for the first time, with a target price of HKD 80, compared to the current price of HKD 58.35 [2][11]. Core Insights - WuXi XDC is positioned to enter a commercialization phase, leveraging its end-to-end integrated CRDMO services and industry-leading technology platform to solidify its leading position in the bioconjugate drug CRDMO sector [1][15]. - The bioconjugate drug industry is experiencing rapid growth, with ADC drugs expected to reach USD 66.2 billion by 2030, and WuXi XDC projected to capture over 24% of the global ADC outsourcing market by 2025 [1][9]. Summary by Relevant Sections Company Overview - WuXi XDC is a joint venture between WuXi Biologics and Hengrui Medicine, focusing on ADC and broader bioconjugate drug markets, providing comprehensive CRDMO services [15][17]. Financial Projections - Revenue projections for WuXi XDC are as follows: - 2024: HKD 4,052 million - 2025: HKD 5,922 million (growth of 46.1%) - 2026: HKD 8,011 million (growth of 35.3%) - 2027: HKD 10,461 million (growth of 30.6%) - Net profit projections are: - 2024: HKD 1,070 million - 2025: HKD 1,481 million (growth of 38.5%) - 2026: HKD 1,989 million (growth of 34.3%) - 2027: HKD 2,600 million (growth of 30.7%) [2][11]. Industry Trends - The bioconjugate drug industry is rapidly expanding, with ADC drugs being the primary focus. The report highlights the emergence of several blockbuster ADC drugs, with six expected to exceed USD 1 billion in sales by 2025 [9][32]. - The outsourcing rate for ADC drugs is projected to remain high at approximately 60%, benefiting companies like WuXi XDC [9][29]. Technological Strengths - WuXi XDC boasts strong technical capabilities with proprietary technologies such as WuXiDARx™, X-LinC conjugation technology, and various payload conjugation platforms, enhancing its competitive edge [7][10]. Capital Expenditure and Growth Strategy - The company plans to invest HKD 1.7 billion in capital expenditures by 2026 to support its global dual-factory production strategy, enhancing its capacity for conjugated raw materials and formulations [7][10]. Market Position - WuXi XDC is expected to have a significant market share in the global ADC outsourcing market, projected to reach over 24% by 2025, reflecting its strong growth trajectory and market demand [1][9].